Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.

Selected additional safety information on regorafenib will be collected and progression-free survival (PFS) will be estimated.
Gastrointestinal Stromal Tumors
DRUG: Regorafenib (BAY73-4506)
The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.

Selected additional safety information on regorafenib will be collected and progression-free survival (PFS) will be estimated.